PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
%
0,00%
Latest
High
Low
Volume
0
Turnover (SEK)
0
Market Value (MSEK)
20,4
Time (Latest trade)

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Stefan Ahlfors

Board

  • Bo Wennergren
  • Staffan Skogvall
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Largest Owners

    Name Capital % Votes % Date
    Staffan Skogvall 39,62 39,62 2026-07-01
    Nordnet Pensionsförsäkring 2,02 2,02 2026-06-26
    Fredrik Hansson 1,93 1,93 2026-06-26
    Arne Arvidsson 1,82 1,82 2026-06-26
    Arne Skogvall Dödsbo 1,73 1,73 2026-06-26
    Monica Billgert 1,31 1,31 2026-06-26
    Investment Aktiebolaget Balticum 1,19 1,19 2026-06-26
    Tommy Johansson 0,89 0,89 2026-06-26
    Fredrik Källström 0,86 0,86 2026-06-26
    Staffan Engelbert Bodén 0,81 0,81 2026-06-26
    ** Powered by Modular Finance

    Insider trading

    *Powered by Modular Finance

    Key Numbers

    *Compiled data from Millistream

    Upcoming reports

    • 2026-07-15

    • 2026-08-20 Interim Report 2026-Q2

    • 2026-11-19 Interim Report 2026-Q3

    • 2027-02-18 Year End Report 2026

    Annual reports, prospectus etc.